Hematology

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions:   Procedure: CS1-CAR T Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 11, 2018 / by / in
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Condition:   Refractory Plasma Cell Myeloma
Interventions:   Drug: Dexamethasone;   Biological: Elotuzumab;   Drug: Pomalidomide
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 10, 2018 / by / in
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Conditions:   Chronic Lymphocytic Leukemia;   Waldenstrom’s Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   B-cell Lymphoma;   Small Lymphocytic Lymphoma
Intervention:   Drug: LOXO-305
Sponsor:   Loxo Oncology, Inc.
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 9, 2018 / by / in
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Conditions:   Non-hodgkin Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Biological: CD19.CAR-multiVST for Group A;   Biological: CD19.CAR-multiVST for Group B
Sponsors:   Baylor College of Medicine;   Texas Children’s Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 8, 2018 / by / in
A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Condition:   Prostatic Neoplasms
Interventions:   Drug: Apalutamide;   Drug: Androgen Deprivation Therapy (ADT);   Drug: Placebo;   Drug: Prednisone;   Drug: Fixed-Dose Combination
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 7, 2018 / by / in
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions:   Drug: Bortezomib;   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Ixazomib;   Other: Quality-of-Life Assessment
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 5, 2018 / by / in
Registry for Adults With Plasma Cell Disorders (PCD’s)

Conditions:   Multiple Myeloma;   Amyloidosis;   Cryoglobulinemia;   Castleman’s Disease;   Light Chain Deposition Disease;   Heavy Chain Deposition Disease;   Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes;   Smoldering Multiple Myeloma;   Plasma Cell Leukemia
Intervention:  
Sponsor:   UNC Lineberger Comprehensive Cancer Center
Recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 4, 2018 / by / in
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions:   Procedure: Stem cell transplantation;   Drug: Itacitinib;   Other: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT);   Other: Human Activity Profile
Sponsors:   Washington University School of Medicine;   Incyte Corporation
Not yet recruiting
ClinicalTrials.gov: Hematology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

December 2, 2018 / by / in